Synexus Announces Clinical Trial Partnership with Northumbria Healthcare
Synexus has formed a partnership with Northumbria Healthcare NHS Foundation Trust to establish a clinical research facility at Hexham General Hospital, in North East England.
Synexus has formed a partnership with Northumbria Healthcare NHS Foundation Trust to establish a clinical research facility at Hexham General Hospital, in North East England. Synexus specializes in the engagement of patients and the running of clinical trials at its own dedicated research centers.
Northumbria Healthcare NHS Foundation Trust is one of the largest NHS foundation trusts in the country and is now the first NHS hospital and community health services provider to forge such a unique clinical trials partnership – with the potential to improve treatment for thousands of patients across the NHS.
Synexus already has dedicated research centers across the UK, Europe and Africa with over 20 years’ experience in running clinical trials with GPs and their patients. The collaboration with Northumbria Healthcare will allow patients in the North East of England access to clinical trials through the trust’s medical specialists.
The new clinical research facility at Hexham General Hospital will open early in 2014 giving opportunities to patients to participate in clinical trials previously unavailable in the NHS.
Synexus CEO Christophe Berthoux said: "We are delighted to have signed this agreement with Northumbria Healthcare NHS Foundation Trust. This reinforces our commitment to working in productive relationships with industry and now with the NHS to offer an improved clinical trial experience for patients. The Department of Health has put an increasing emphasis on the importance of clinical trials in the UK and we are very keen to be able to combine our significant experience and heritage with the positive reputation of the NHS.”
Chief Executive of Northumbria Healthcare NHS Foundation Trust, Jim Mackey said: “This is an excellent opportunity for the trust and we are delighted to be the first NHS trust to partner with Synexus. Clinical trials play an important role in the NHS and we are pleased that we are helping to not only improve the quality of life for patients but also have input in developing medicines to help patients for years to come. Our existing clinical research department has gone from strength to strength in the last few years, bringing major benefits to patients, and this partnership will help us to build on that strong foundation.”
This new partnership with Synexus builds on the high quality clinical trials already supported by Northumbria Healthcare NHS Foundation Trust in a broad range of conditions such as Parkinson’s disease, stroke and cancer. The trust has also previously been awarded National Institute for Health Research (NIHR) funding to lead on a number of national research projects regarding important healthcare issues that affect our population.
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
